Puddu Alessandra, Sanguineti Roberta, Montecucco Fabrizio, Viviani Giorgio Luciano
First Clinic of Internal Medicine, Department of Internal Medicine, University of Genoa, IRCCS Azienda Ospedaliera Universitaria San Martino, 6 Viale Benedetto XV, 16143 Genoa, Italy.
First Clinic of Internal Medicine, Department of Internal Medicine, University of Genoa, IRCCS Azienda Ospedaliera Universitaria San Martino, 6 Viale Benedetto XV, 16143 Genoa, Italy ; Division of Cardiology, Foundation for Medical Researches, Department of Medical Specialties, Geneva University Hospitals, 64 Avenue de la Roseraie, 1211 Geneva, Switzerland ; Division of Laboratory Medicine, Department of Genetics and Laboratory Medicine, Geneva University Hospitals, 4 Rue Gabrielle-Perret-Gentil, 1205 Geneva, Switzerland.
Mediators Inflamm. 2014;2014:162021. doi: 10.1155/2014/162021. Epub 2014 Aug 17.
In type 2 diabetes, hyperglycemia, insulin resistance, increased inflammation, and oxidative stress were shown to be associated with the progressive deterioration of beta-cell function and mass. Short-chain fatty acids (SCFAs) are organic fatty acids produced in the distal gut by bacterial fermentation of macrofibrous material that might improve type 2 diabetes features. Their main beneficial activities were identified in the decrease of serum levels of glucose, insulin resistance as well as inflammation, and increase in protective Glucagon-like peptide-1 (GLP-1) secretion. In this review, we updated evidence on the effects of SCFAs potentially improving metabolic control in type 2 diabetes.
在2型糖尿病中，高血糖、胰岛素抵抗、炎症增加和氧化应激与β细胞功能和质量的逐渐恶化有关。短链脂肪酸（SCFAs）是由肠道远端的细菌对大纤维物质进行发酵产生的有机脂肪酸，可能改善2型糖尿病的特征。它们的主要有益作用体现在降低血清葡萄糖水平、胰岛素抵抗以及炎症，并增加具有保护作用的胰高血糖素样肽-１（GLP-1）的分泌。在本综述中，我们更新了关于短链脂肪酸可能改善2型糖尿病代谢控制作用的证据。
